By Giulia Petroni 
 

Sanofi SA said late Wednesday that the U.S. Food and Drug Administration has approved Sarclisa, or isatuximab, in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma.

The French pharmaceutical company said the treatment is for adult patients with RRMM who have already received one to three prior therapies.

According to the Phase 3 Ikema study, the Sarclisa combination treatment allows for the reduction of risk of disease progression or death by 45%, Sanofi said.

The FDA had previously approved the Sarclisa regimen for the treatment of adults with RRMM who have received at least two prior therapies.

 

Write to Giulia Petroni at giulia.petroni@wsj.com

 

(END) Dow Jones Newswires

April 01, 2021 01:22 ET (05:22 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Jun 2021 to Jul 2021 Click Here for more Sanofi Charts.
Sanofi (EU:SAN)
Historical Stock Chart
From Jul 2020 to Jul 2021 Click Here for more Sanofi Charts.